TY - JOUR
T1 - The role of chemotherapy in treatment of advanced breast cancer
T2 - an overview for clinical practice
AU - Claessens, Anouk K. M.
AU - Ibragimova, Khava I. E.
AU - Geurts, Sandra M. E.
AU - Bos, Monique E. M. M.
AU - Erdkamp, Frans L. G.
AU - Tjan-Heijnen, Vivianne C. G.
N1 - Publisher Copyright:
© 2020 The Author(s)
PY - 2020/9
Y1 - 2020/9
N2 - This review aims to evaluate the role of chemotherapy-containing regimens in the treatment of advanced breast cancer (ABC), with the purpose to optimize selection, sequencing and duration of treatment with the currently available agents for clinical practice. Data from observational as well as randomized phase II and III studies were included. Chemotherapy yielded a median overall survival (OS) of 2 years in registration studies, with comparable efficacy of different agents. Combining chemotherapy agents did not yield OS improvement and caused greater toxicity compared with single-agent chemotherapy. Continuing chemotherapy fill progression or unacceptable toxicity generated greater efficacy without detrimental impact on quality of life compared with a limited amount of cycles. In real-world studies, benefits after third-line chemotherapy were modest compared with first- and second-line. Furthermore, effects of previous chemotherapy predicted effects of next-line therapy in real-world. Physicians increasingly prescribed capecitabine or taxanes as first- or second-line chemotherapy over time.
AB - This review aims to evaluate the role of chemotherapy-containing regimens in the treatment of advanced breast cancer (ABC), with the purpose to optimize selection, sequencing and duration of treatment with the currently available agents for clinical practice. Data from observational as well as randomized phase II and III studies were included. Chemotherapy yielded a median overall survival (OS) of 2 years in registration studies, with comparable efficacy of different agents. Combining chemotherapy agents did not yield OS improvement and caused greater toxicity compared with single-agent chemotherapy. Continuing chemotherapy fill progression or unacceptable toxicity generated greater efficacy without detrimental impact on quality of life compared with a limited amount of cycles. In real-world studies, benefits after third-line chemotherapy were modest compared with first- and second-line. Furthermore, effects of previous chemotherapy predicted effects of next-line therapy in real-world. Physicians increasingly prescribed capecitabine or taxanes as first- or second-line chemotherapy over time.
KW - Advanced breast cancer
KW - Chemotherapy
KW - Duration
KW - Sequence
KW - Real-world
KW - PHASE-III TRIAL
KW - QUALITY-OF-LIFE
KW - GEMCITABINE PLUS PACLITAXEL
KW - SINGLE-AGENT CHEMOTHERAPY
KW - 1ST-LINE TREATMENT
KW - RANDOMIZED-TRIAL
KW - DOUBLE-BLIND
KW - CONVENTIONAL DOXORUBICIN
KW - MAINTENANCE CHEMOTHERAPY
KW - COMBINATION CHEMOTHERAPY
U2 - 10.1016/j.critrevonc.2020.102988
DO - 10.1016/j.critrevonc.2020.102988
M3 - (Systematic) Review article
C2 - 32599374
SN - 1040-8428
VL - 153
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
M1 - 102988
ER -